Developer docs
API playgroundTry for free, no card

Search company profiles

StrideBio

Full company profile

uuid0000rvq

Namestring
StrideBio
Websiteurl
stridebio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

StrideBio is a gene therapy company founded in 2015 and headquartered in Durham, North Carolina, that develops engineered adeno-associated virus (AAV) vectors for the treatment of life-threatening genetic and neurological diseases. The company's core technology is the STRIVE Capsid Platform, a proprietary capsid engineering system intended to improve vector targeting, tissue specificity, and immune evasion in gene therapy delivery. StrideBio operates a Therapeutic Pipeline of gene therapy candidates built on this platform, supported by in-house AAV Manufacturing capabilities that provide vertical integration over vector supply and quality.

StrideBio serves patients with life-threatening diseases as its end-user population, while its primary commercial counterparties are pharmaceutical collaborators and equity capital providers. The company has raised approximately $97.2 million across three disclosed financing rounds (2017, 2018, 2021), with strategic pharma investors including Sarepta Therapeutics, Takeda Ventures, and UCB Ventures participating alongside venture capital firms such as Northpond Ventures, Novo Holdings, and Hatteras Venture Partners. The leadership team comprises CEO Mark Velleca, COO William Monteith, and co-founders Aravind Asokan and Mavis Agbandje, lending scientific and operational depth.

The business model is pre-revenue and dependent on equity financing and the prospective development of partnership, licensing, or product revenue as the pipeline advances. No pricing, licensing economics, or product commercialization has been disclosed, consistent with an early-stage biotech whose enterprise value is tied to platform validation, pipeline progression, and eventual clinical or commercial milestones rather than current sales. The company operates within the broader AAV vector manufacturing market, which is projected to grow from $1.03 billion in 2023 to $10.07 billion by 2034.

Short descriptiontext

StrideBio is a gene therapy company developing engineered AAV vectors using its proprietary STRIVE Capsid Platform to deliver genetic medicines for patients with life-threatening diseases. It is a pre-revenue, privately held biotech backed by strategic pharma and venture investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
gene therapy development, AAV vector engineering, capsid platform technology, genetic medicines pipeline, viral vector manufacturing
Industry3 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Gene Therapy Development
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

StrideBio develops engineered adeno-associated virus (AAV) vector-based gene therapies using its proprietary STRIVE™ Capsid Platform for targeted gene delivery. The company operates in-house AAV manufacturing to support its therapeutic pipeline of gene therapy candidates aimed at life-threatening genetic and neurological diseases.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

StrideBio is a gene therapy company developing a portfolio of treatments for life-threatening diseases. The company's offerings center around the STRIVETM Capsid Platform, which enables engineering of AAV vectors for targeted gene delivery, supported by internal AAV Manufacturing capabilities. The Therapeutic Pipeline represents the company's drug development candidates derived from this platform.

Product and service3 records
1STRIVE™ Capsid Platform
CategoryCore Platform
2Therapeutic Pipeline
CategoryCore Product
3AAV Manufacturing
CategoryCore Service
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage AAV gene therapy company with proprietary NAV Technology platform for capsid engineering. Direct competitor in engineered AAV vectors for rare diseases and CNS indications, and a benchmark for platform-to-product translation.

TypeDirect peer
Description

Gene therapy company developing AAV-based treatments for CNS diseases, with a proprietary capsid discovery platform (TRACER). Closely comparable in capsid engineering focus, therapeutic area, and pipeline strategy.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company with a Therapeutic Vector Evolution platform for custom capsid design. Direct competitor in tissue-targeted AAV capsid engineering for ophthalmology, cardiology, and pulmonology.

TypeDirect peer
Description

Gene therapy company built around an engineered AAV capsid platform with CNS and neuromuscular focus. Closely comparable to StrideBio as a capsid-engineering-first company targeting similar indications.

TypeDirect peer
Description

Developer of rationally engineered AAV capsids and gene therapies for CNS and muscle diseases. Direct competitor in the capsid-engineering niche with comparable platform-to-pipeline structure.

TypeDirect peer
Description

Clinical-stage gene therapy company with both AAV and lentiviral platforms; one of the few gene therapy companies with a commercial product (Hemgenix). Comparable as an established AAV developer with manufacturing infrastructure.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company focused on CNS disorders, with capsid selection tied to Penn/Gene Therapy Program collaborations. Comparable in AAV delivery focus and rare/CNS indication strategy.

TypeDirect peer
Description

Gene therapy company developing AAV-based treatments primarily for Duchenne muscular dystrophy and other neuromuscular diseases. Comparable in AAV delivery modality and rare-disease therapeutic focus.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company developing treatments for CNS and rare diseases, leveraging partnerships with UT Southwestern. Comparable in AAV delivery, indication focus, and platform-based pipeline approach.

TypeBroad incumbent
Description

Commercial-stage leader in AAV-based gene therapy for Duchenne muscular dystrophy (Elevidys) and other neuromuscular diseases. Functions as both an investor in StrideBio and an incumbent benchmark for AAV gene therapy commercialization.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StrideBio

Gene Therapy Developmentstridebio.com

StrideBio is a gene therapy company developing engineered AAV vectors using its proprietary STRIVE Capsid Platform to deliver genetic medicines for patients with life-threatening diseases. It is a pre-revenue, privately held biotech backed by strategic pharma and venture investors.

What StrideBio does

StrideBio is a gene therapy company founded in 2015 and headquartered in Durham, North Carolina, that develops engineered adeno-associated virus (AAV) vectors for the treatment of life-threatening genetic and neurological diseases. The company's core technology is the STRIVE Capsid Platform, a proprietary capsid engineering system intended to improve vector targeting, tissue specificity, and immune evasion in gene therapy delivery. StrideBio operates a Therapeutic Pipeline of gene therapy candidates built on this platform, supported by in-house AAV Manufacturing capabilities that provide vertical integration over vector supply and quality.

StrideBio serves patients with life-threatening diseases as its end-user population, while its primary commercial counterparties are pharmaceutical collaborators and equity capital providers. The company has raised approximately $97.2 million across three disclosed financing rounds (2017, 2018, 2021), with strategic pharma investors including Sarepta Therapeutics, Takeda Ventures, and UCB Ventures participating alongside venture capital firms such as Northpond Ventures, Novo Holdings, and Hatteras Venture Partners. The leadership team comprises CEO Mark Velleca, COO William Monteith, and co-founders Aravind Asokan and Mavis Agbandje, lending scientific and operational depth.

The business model is pre-revenue and dependent on equity financing and the prospective development of partnership, licensing, or product revenue as the pipeline advances. No pricing, licensing economics, or product commercialization has been disclosed, consistent with an early-stage biotech whose enterprise value is tied to platform validation, pipeline progression, and eventual clinical or commercial milestones rather than current sales. The company operates within the broader AAV vector manufacturing market, which is projected to grow from $1.03 billion in 2023 to $10.07 billion by 2034.

StrideBio firmographics

Firmographics
Name
StrideBio
Website
https://stridebio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
StrideBio is a gene therapy company developing engineered AAV vectors using its proprietary STRIVE Capsid Platform to deliver genetic medicines for patients with life-threatening diseases. It is a pre-revenue, privately held biotech backed by strategic pharma and venture investors.
Ownership category
akta.pro rank

StrideBio industry classification

Industry
Product category
Gene Therapy Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)

Keywords

  • Gene therapy development
  • AAV vector engineering
  • Capsid platform technology
  • Genetic medicines pipeline
  • Viral vector manufacturing

Where StrideBio is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Markets served

StrideBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

StrideBio product offering

Product offering

Core offering

StrideBio develops engineered adeno-associated virus (AAV) vector-based gene therapies using its proprietary STRIVE™ Capsid Platform for targeted gene delivery. The company operates in-house AAV manufacturing to support its therapeutic pipeline of gene therapy candidates aimed at life-threatening genetic and neurological diseases.

Product overview

StrideBio is a gene therapy company developing a portfolio of treatments for life-threatening diseases. The company's offerings center around the STRIVETM Capsid Platform, which enables engineering of AAV vectors for targeted gene delivery, supported by internal AAV Manufacturing capabilities. The Therapeutic Pipeline represents the company's drug development candidates derived from this platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • STRIVE™ Capsid Platform
  • Therapeutic Pipeline
  • AAV Manufacturing

Companies that use StrideBio

Customer profile

Segments1 record

Ideal customer profiles2 records

StrideBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

StrideBio partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

StrideBio competitors and assessment

Company assessment

Direct peers

  • REGENXBIO: Clinical-stage AAV gene therapy company with proprietary NAV Technology platform for capsid engineering. Direct competitor in engineered AAV vectors for rare diseases and CNS indications, and a benchmark for platform-to-product translation.
  • Voyager Therapeutics: Gene therapy company developing AAV-based treatments for CNS diseases, with a proprietary capsid discovery platform (TRACER). Closely comparable in capsid engineering focus, therapeutic area, and pipeline strategy.
  • 4D Molecular Therapeutics: Clinical-stage AAV gene therapy company with a Therapeutic Vector Evolution platform for custom capsid design. Direct competitor in tissue-targeted AAV capsid engineering for ophthalmology, cardiology, and pulmonology.
  • Capsida Biotherapeutics: Gene therapy company built around an engineered AAV capsid platform with CNS and neuromuscular focus. Closely comparable to StrideBio as a capsid-engineering-first company targeting similar indications.
  • Affinia Therapeutics: Developer of rationally engineered AAV capsids and gene therapies for CNS and muscle diseases. Direct competitor in the capsid-engineering niche with comparable platform-to-pipeline structure.
  • uniQure: Clinical-stage gene therapy company with both AAV and lentiviral platforms; one of the few gene therapy companies with a commercial product (Hemgenix). Comparable as an established AAV developer with manufacturing infrastructure.
  • Passage Bio: Clinical-stage AAV gene therapy company focused on CNS disorders, with capsid selection tied to Penn/Gene Therapy Program collaborations. Comparable in AAV delivery focus and rare/CNS indication strategy.
  • Solid Biosciences: Gene therapy company developing AAV-based treatments primarily for Duchenne muscular dystrophy and other neuromuscular diseases. Comparable in AAV delivery modality and rare-disease therapeutic focus.
  • Taysha Gene Therapies: Clinical-stage AAV gene therapy company developing treatments for CNS and rare diseases, leveraging partnerships with UT Southwestern. Comparable in AAV delivery, indication focus, and platform-based pipeline approach.

Broad incumbents

  • Sarepta Therapeutics: Commercial-stage leader in AAV-based gene therapy for Duchenne muscular dystrophy (Elevidys) and other neuromuscular diseases. Functions as both an investor in StrideBio and an incumbent benchmark for AAV gene therapy commercialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

StrideBio social profiles

Digital presence

StrideBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StrideBio leadership team

Management profile

Number of profiles

Profiles5 records

StrideBio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StrideBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StrideBio

What does StrideBio do?

StrideBio develops engineered adeno-associated virus (AAV) vector-based gene therapies using its proprietary STRIVE™ Capsid Platform for targeted gene delivery. The company operates in-house AAV manufacturing to support its therapeutic pipeline of gene therapy candidates aimed at life-threatening genetic and neurological diseases.

Is StrideBio a public or private company?

StrideBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was StrideBio founded?

StrideBio was founded in 2015. It employs 1 to 10 people.

Where is StrideBio based?

StrideBio is headquartered in Durham, United States, in the North America region.

Who are StrideBio's main competitors?

Direct peers on record are REGENXBIO, Voyager Therapeutics, 4D Molecular Therapeutics, Capsida Biotherapeutics, Affinia Therapeutics, uniQure, Passage Bio, Solid Biosciences and Taysha Gene Therapies. Sarepta Therapeutics is listed as a broad incumbent.

Does StrideBio have an API?

No public API is recorded for StrideBio.

What industry is StrideBio in?

StrideBio's product category is Gene Therapy Development. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Endpoints NewsGink­go snaps up gene ther­a­py vec­tor as­sets from Stride­BioGinkgo Bioworks announced on Wednesday that it is acquiring viral vector assets from StrideBio. The acquisition is part of Ginkgo's ongoing push into gene therapy services.BioPharma DiveGinkgo grows its gene therapy offerings with StrideBio dealGinkgo Bioworks has acquired the technology of StrideBio aimed at enhancing gene therapies, announced on Wednesday. This deal includes tools for developing capsids, essential for delivering genetic material effectively, along with StrideBio's library of capsids and intellectual property for a preclinical drug. Ginkgo plans to outlicense the drug to a commercial partner instead of developing it internally.BioSpaceGinkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio’s AAV Capsid Discovery and Engineering Platform AssetsGinkgo Bioworks acquired StrideBio's AAV capsid discovery and engineering platform assets, with a secondary close pending transfer of in-license agreements. The deal includes a library of optimized capsids and IP for a lead preclinical asset for Arrhythmogenic Right Ventricular Cardiomyopathy, which Ginkgo plans to sell or outlicense.PR NewswireGinkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV Capsid Discovery and Engineering Platform AssetsGinkgo Bioworks acquired StrideBio's AAV capsid discovery and engineering platform assets, including a library of optimized capsids and IP for a lead preclinical asset for Arrhythmogenic Right Ventricular Cardiomyopathy. Ginkgo plans to sell or outlicense the ARVC asset to a commercial partner. The acquisition aims to enhance Ginkgo's end-to-end AAV gene therapy development capabilities.BioSpaceStrideBio Announces Mark Velleca, M.D., Ph.D., as Chief Executive OfficerStrideBio appointed Mark Velleca, M.D., Ph.D., as CEO, succeeding Sapan Shah, who is leaving to pursue other opportunities. Velleca joins from Hatteras Venture Partners and previously led G1 Therapeutics. He will lead the company's gene therapy pipeline.PR NewswireStrideBio Announces Closing of $81.5M Series B FinancingStrideBio, Inc. announced the closing of an oversubscribed $81.5 million Series B financing round co-led by Northpond Ventures and Novo Holdings A/S. The funds will be used to advance four new wholly-owned gene therapy programs into the clinic and expand GMP manufacturing capacity. This investment supports the company's growth and the development of its proprietary STRIVE™ platform for engineered adeno-associated virus (AAV) capsids.PR NewswireStrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating OfficerStrideBio, Inc., a gene therapy company focused on adeno-associated virus-based therapies for rare diseases, announced the appointment of William (Bill) Monteith as Chief Operating Officer. Monteith brings nearly 40 years of experience in clinical development and commercial manufacturing across small molecules, biologics, and cell and gene therapies, joining from Cellectis where he served as Executive Vice President of Technical Operations. The appointment supports StrideBio's expansion as it advances its portfolio of gene therapy programs toward clinical development and commercialization.PR NewswireStrideBio Appoints Maritza Mcintyre, Ph.D., As Chief Development OfficerStrideBio, Inc. announced the appointment of Maritza McIntyre, Ph.D. as Chief Development Officer, a newly created role at the gene therapy company. Dr. McIntyre brings over 20 years of experience in gene therapy development and regulation, having previously served as Chief of the Gene Therapy Branch at the U.S. FDA, Vice President at REGENXBIO, and Executive Vice President at Bamboo Therapeutics. The appointment reflects StrideBio's strategy to build internal capabilities as it advances its pipeline of novel AAV-based gene therapies toward clinical development.PR NewswireStrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological DiseasesStrideBio, Inc. signed a collaboration and license agreement with Takeda Pharmaceutical Company Limited to develop in vivo AAV-based gene therapies for Friedreich's Ataxia and two additional undisclosed neurological disease targets. Under the terms, StrideBio will lead AAV capsid development, non-clinical work and manufacturing, while Takeda will handle clinical development and commercialization, receiving up to approximately $30 million in upfront and near-term preclinical milestones plus up to $680 million in future development and commercial milestones plus royalties on worldwide net sales.PR NewswireStrideBio Appoints Sapan Shah, Ph.D. as Chief Executive OfficerStrideBio, Inc. has appointed Sapan Shah, Ph.D., as its new Chief Executive Officer and a member of the company's board. Dr. Shah brings over 20 years of experience in the pharmaceutical and biotechnology industry, having previously held leadership roles in several companies, and is expected to support StrideBio's expansion of its gene therapy programs. The appointment comes at a crucial time as StrideBio aims to advance multiple preclinical programs into clinical trials and enhance its in-house manufacturing capabilities.